The benefits of aspirin therapy may exceed the potential risk in women with endometrial cancer despite conflicting findings according to a recent review that examined aspirin use and endometrial cancer risk and survival. Researchers reviewed the evidence for the association between endometrial cancer and obesity, the pharmacological differences between regular- and low-dose aspirin, as well as the potential anti-tumor mechanism of aspirin. Among their conclusions:

• Aspirin was shown to have chemo-preventive effects on colorectal cancer.
• Aspirin can suppress platelet activation.
• Aspirin can indirectly inhibit prostaglandin E₂, an obesity-related inflammatory marker.
• Aspirin may improve the survival of women with endometrial adenocarcinoma.
• Aspirin use may have a secondary benefit for obesity-related comorbidities including cardiovascular disease in this study population.